Goyal RK, Wheeler SB, Kohler RE, Lich KH, Lin CC, Reeder-Hayes K, Meyer AM, Mayer DK. Health care utilization from chemotherapy-related adverse events among low-income breast cancer patients: effect of enrollment in a medical home program. N C Med J. 2014 Jul;75(4):231-8.
Jimenez-Murcia S, Fernandez-Aranda F, Granero R, Choliz M, La Verde M, Aguglia E, Signorelli MS, Sa GM, Aymami N, Gomez-Pena M, Del Pino-Gutierrez A, Moragas L, Fagundo AB, Sauchelli S, Fernandez-Formoso JA, Menchon JM. Video game addiction in gambling disorder: clinical, psychopathological, and personality correlates. Biomed Res Int. 2014;2014:315062. doi: 10.1155/2014/315062
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Ferris M, Patel UD, Massengill S, Gipson D, Conley W, Layton JB, Nagaraj S, Primack W. Pediatric chronic kidney disease in North Carolina. N C Med J. 2008 May;69(3):208-14.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.